Engineered antibodies with reduced immunogenicity and methods of making

Details for Australian Patent Application No. 2009313389 (hide)

Owner Alexion Pharmaceuticals, Inc.

Inventors Rother, Russell P.

Agent Shelston IP

Pub. Number AU-A-2009313389

PCT Pub. Number WO2010/054212

Priority 61/198,466 06.11.08 US

Filing date 6 November 2009

Wipo publication date 14 May 2010

International Classifications

C07K 16/46 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - Hybrid immunoglobulins

C07K 2/00 (2006.01) Peptides of undefined number of amino acids

C12N 15/13 (2006.01) Mutation or genetic engineering - Immunoglobulins

Event Publications

2 June 2011 PCT application entered the National Phase

  PCT publication WO2010/054212 Priority application(s): WO2010/054212

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009313391-Systems and methods for treatment of prostatic tissue

2009313384-Automatically pulsing different aspiration levels to an ocular probe